B
BioTheryX
A clinical-stage company harnessing deep expertise in Targeted Protein Degradation to restore protein homeostasis in order to treat a wide range of diseases
About BioTheryX
Biotheryx is a biotechnology startup that specializes in the design and development of targeted protein degraders. These are a new class of drugs that work by binding to disease-causing proteins in the body and marking them for destruction. The company's main focus is on developing treatments for cancer and inflammatory diseases, two areas with significant unmet medical needs.
Biotheryx's proprietary PRODEGY (Protein Degrader Technology) platform is at the heart of its business. This platform uses the company's expertise in modulating a protein called Cereblon to design targeted protein degraders. Modulating means altering the activity of Cereblon in ways that have never been done before, which could lead to new treatments for diseases.
The company generates revenue by developing a pipeline of these protein degraders and partnering with other companies to bring them to market. For example, in April 2023, Biotheryx announced a research collaboration and license agreement with Incyte, a pharmaceutical company, for the discovery of targeted protein degraders for novel oncology targets.
Biotheryx also presents its preclinical findings at various scientific meetings, which helps to raise its profile in the biotech industry and attract potential partners and investors.
In summary, Biotheryx operates in the biotech market, serving clients in the pharmaceutical industry. Its business model revolves around the development of targeted protein degraders for the treatment of cancer and inflammatory diseases, and it makes money through partnerships and licensing agreements.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2008
- Headquarters
- San Diego, United States
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 69.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | May 2021 | $92M | $368M | Tekla Capital Management · Point72 Ventures · Alexandria Venture Investments · Avidity Partners | ↗ |
| SERIES DOther financing | Jul 2020 | $35M | $140M | MSD Partners | ↗ |
Growth signals
Latest recorded traffic for BioTheryX is 3.9K monthly website visits, up 116.7% over the last three months. BioTheryX's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
BioTheryX in the San Diego ecosystem
The BioTheryX office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series B and later13 investors entered at this stage
MSD Partners
Farallon Capital Management- TMTekla Capital Management
Point72 Ventures
Alexandria Venture Investments
Avidity Partners
Deep Track Capital
Rock Springs CapitalJanus Henderson Investors
- IIIrving Investors
Lumira Ventures
Wedbush Ventures
Surveyor Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioTheryX on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioTheryX’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










